Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.

 

whitepaper image
download icon

Download case study

Parkinson's disease study

Sano ran a neurodegenerative disease testing program to build a cohort for natural history studies and clinical trial enrollment, targeting rare genetic subtypes like LRRK2 and GBA across a multi-country study in the US and Canada. The work meant overcoming the high screen failure rates typical of traditional trial settings, keeping patients engaged until the right study became available, and bringing HCPs who weren't always versed in genetics along for the journey.

We built an umbrella screening program with an optimized pre-screener, made participation easy with non-invasive at-home DNA testing, and kept patients informed through a virtual waiting room and white-glove concierge support, while partnering with HCPs and community leaders to reach populations with a family history of PD.

Download the case study to see how Sano is helping accelerate research into genetic Parkinson's disease.

 

Group 5488